Replies to post #140856 on Biotech Values

[iandy]

If someone were to tell me three years ago that Elan would:

1) Sell 50.1% of its rights to all of their Alzheimer’s treatments to J&J for $885 million - with J&J footing most of the development costs.

2) Sell its drug technology unit for around $960 million.

3) Get their long tern debt under $600 million.

4) and sell around $1.6 billions dollars worth of Tysabri per year.

I would have expected they would finally turn a profit.

[masterlongevity]

yes, how do you spend $50M in RnD in Q1 with absolutely ZERO drugs in clinical development?